Back to top
more

DexCom (DXCM)

(Real Time Quote from BATS)

$68.27 USD

68.27
3,200,497

-0.73 (-1.06%)

Updated Nov 6, 2024 03:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Dexcom's (DXCM) Digital Network Benefits From Latest FDA Nod

by Zacks Equity Research

Recent regulatory clearance of Dexcom's (DXCM) real-time APIs is expected to aid diabetics as well as their care providers in accessing GCM data.

New Strong Sell Stocks for July 13th

by Zacks Equity Research

ONEM, BABA, DXCM, ORAN, and MTH have been added to the Zacks Rank #5 (Strong Sell) List on July 13, 2021

New Strong Sell Stocks for July 6th

by Zacks Equity Research

DXCM, GP, PHR, RAD, and MAXR have been added to the Zacks Rank #5 (Strong Sell) List on July 6, 2021

Debanjana Dey headshot

Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus

by Debanjana Dey

CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.

Dexcom's (DXCM) G6 CGM System Gets Coverage in British Columbia

by Zacks Equity Research

Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.

    DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    DexCom's (DXCM) first-quarter results benefit from domestic and international revenue growth.

    DexCom (DXCM) Surpasses Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    DexCom (DXCM) delivered earnings and revenue surprises of 6.45% and 4.63%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

    Trina Mukherjee headshot

    Medical Products' Apr 29 Earnings Roster: TMO, BAX & More

    by Trina Mukherjee

    The Medical Product companies' first-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

    Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands

    by Zacks Equity Research

    Zacks.com featured highlights include: MercadoLibre, HealthEquity, DexCom, StoneCo and Las Vegas Sands

    DexCom (DXCM) is in Overbought Territory: What's Next?

    by Zacks Equity Research

    DexCom (DXCM) has moved higher as of late, but there could definitely be trouble on the horizon for this company

    Rimmi Singhi headshot

    5 Toxic Stocks That Could Break the Bank

    by Rimmi Singhi

    Steer clear of toxic stocks like MELI, HQY, DXCM, STNE and LVS to safeguard your portfolio.

    DexCom (DXCM) to Report Q1 Earnings: What's in the Cards?

    by Zacks Equity Research

    DexCom's (DXCM) first-quarter results are likely to reflect rising global awareness of its real-time CGM.

    Analysts Estimate DexCom (DXCM) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    DexCom (DXCM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Rimmi Singhi headshot

    Keep Your Portfolio Protected From These Toxic Stocks

    by Rimmi Singhi

    Toxic stocks are vulnerable to external shocks and are burdened with huge debts. It's important to ensure that you safeguard your portfolio from such stocks.

    Rimmi Singhi headshot

    4 Toxic Stocks That Could Ruin Your Portfolio

    by Rimmi Singhi

    Toxic stocks usually carry huge debt load and are vulnerable to external shocks. They should be timely discarded from one's portfolio to avoid wealth erosion.

    DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat

    by Zacks Equity Research

    DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.

    DexCom (DXCM) Meets Q4 Earnings Estimates

    by Zacks Equity Research

    DexCom (DXCM) delivered earnings and revenue surprises of 0.00% and 1.88%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    Trina Mukherjee headshot

    Medical Products' Feb 11 Earnings Roster: DXCM, LH & More

    by Trina Mukherjee

    The Medical Product companies' fourth-quarter results are likely to reflect huge adoption of COVID-19 related healthcare-support products and services despite the impact of the ongoing pandemic.

    DexCom (DXCM) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    DexCom's (DXCM) fourth-quarter results are likely to reflect rising global awareness of its real-time CGM.

    Stock Market News for Jan 15, 2021

    by Zacks Equity Research

    Benchmarks closed in the red on Thursday, as rise in weekly initial jobless claims suggested that economic growth is stalling again.

    DexCom (DXCM) Posts Solid Preliminary Q4 and 2020 Revenues

    by Zacks Equity Research

    DexCom (DXCM) posts solid fourth-quarter and full-year 2020 revenue data on the back of resilience shown in the face of the COVID-19 induced challenges.

    DexCom (DXCM) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    DexCom (DXCM) closed the most recent trading day at $388.09, moving +0.24% from the previous trading session.

    DexCom (DXCM) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    In the latest trading session, DexCom (DXCM) closed at $355.02, marking a -0.27% move from the previous day.

    DexCom (DXCM) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    DexCom (DXCM) closed at $358.57 in the latest trading session, marking a +0.18% move from the prior day.

    Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom

    by Zacks Equity Research

    Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom